Chapter 35 — Case Study 1: From Idea to Pharmacy — A Drug's Lifecycle

"From identification of a target, to discovery of a hit, to optimization of a lead, to clinical trials, to FDA approval — a drug's journey is a 10-15 year obstacle course where 99.99% of candidates fail. Of every 10,000 compounds tested, only ~1 reaches a patient. The chemistry of how that 1 succeeds is the chemistry of this textbook." — paraphrase from a drug discovery overview

The pharmaceutical industry's R&D process is one of the most technically demanding endeavors in human history. It integrates organic chemistry, biology, pharmacology, computer science, statistics, regulatory science, and clinical medicine into a process that takes 10-15 years and costs $1-3 billion per approved drug. This case study traces a drug's lifecycle from identification to pharmacy, with focus on the chemistry at each step.

Step 1: Target identification (Years 1-2)

The first question: what disease are we trying to treat? And what protein (or other biological target) should we modulate to affect that disease?

Sources of targets: - Genome-wide association studies (GWAS): identify genetic variants linked to disease. - Functional genomics: knock out genes in cells or animals; observe phenotypes. - Disease biology: existing knowledge of pathways involved in disease. - Repurposing: a target known for one disease may be relevant to another.

Once a target is chosen, validation: confirm it is "druggable" (can be modulated by small molecules) and "disease-modifying" (modulating it actually helps).

Druggability factors: - A small-molecule binding pocket (typically a hydrophobic cleft). - Knowledge of protein structure (or AlphaFold predicts it). - Catalytic activity that can be inhibited (kinase, protease, etc.). - Or a binding partner that can be displaced.

Examples of druggable targets

  • Kinases (~600 in human genome; ~400 are druggable). Many cancer drugs target kinases.
  • GPCRs (~800 in human genome). ~30% of approved drugs target GPCRs.
  • Nuclear receptors (~50). Steroid hormones, vitamin D, thyroid.
  • Ion channels. Local anesthetics, calcium-channel blockers.
  • Proteases. HIV protease, hepatitis C protease.
  • Many enzymes. HMG-CoA reductase, MAO, etc.

Step 2: Hit discovery (Years 2-3)

Given a validated target, find a chemical "starter" — a hit compound that binds the target with at least micromolar affinity.

Methods:

High-throughput screening (HTS)

Screen a library of millions of small molecules against the target in a biochemical or cellular assay. Top hits (~0.01-0.1% of compounds) become starting points.

Fragment-based drug discovery (FBDD)

Screen smaller libraries (~1000-10000 fragments, MW 150-300) using sensitive methods (X-ray, NMR, SPR). Fragment hits are weaker (millimolar affinity) but can be grown into potent leads.

Virtual screening

Computational docking of millions of compounds into the target's binding site. Top scorers are tested experimentally.

AI-driven discovery

Machine learning models predict which compounds will bind. Trained on past binding data; predicts for novel compounds. 2020s boom in this approach.

Natural products

Search natural product libraries for activity. Many drugs (taxol, statins, penicillin) originated this way.

Step 3: Hit-to-lead optimization (Years 3-5)

Given a hit (micromolar binder), optimize it to nanomolar potency + drug-like properties. This is the medicinal chemistry phase — and is mostly the chemistry of Chapters 24-30.

Process

  1. Make 10-100 analogs of the hit (vary methyl groups, substituents, ring systems).
  2. Test each for: potency (Kd, IC₅₀), selectivity (vs. off-targets), and key ADME parameters (logP, solubility, metabolic stability).
  3. Identify the SAR (which positions matter for activity, which for selectivity, etc.).
  4. Choose the best 1-2 compounds as "lead candidates."

The chemistry: SAR exploration uses standard organic synthesis. Each analog typically takes 3-7 days to make and test.

Example: from imatinib's discovery to Gleevec

Imatinib (Gleevec) is the first kinase inhibitor and a paradigm for rational design. - Target: BCR-ABL kinase (a fusion protein driving chronic myelogenous leukemia). - Hit: a 2-phenylaminopyrimidine series; weakly inhibited kinases. - Lead optimization: ~200 analogs over years; balanced potency, selectivity, ADME. - Final compound: imatinib, with selectivity for BCR-ABL over related kinases. - Approved 2001. Transformed CML treatment from a fatal disease to a chronic condition.

Step 4: Lead optimization (Years 5-7)

Optimize the lead for clinical viability. Key parameters:

Potency

Should be sub-micromolar in cells (not just in biochemical assays).

Selectivity

Should not bind significant off-targets at therapeutic concentrations.

ADME (Pharmacokinetics)

  • Absorption: should be orally bioavailable (>20% F).
  • Distribution: appropriate volume of distribution; reaches the target tissue.
  • Metabolism: stable enough for once-daily dosing (or whatever frequency).
  • Excretion: doesn't accumulate.

Safety

  • No carcinogenicity.
  • No teratogenicity (don't repeat thalidomide!).
  • Acceptable side-effect profile.

This iterative phase typically runs 2-3 years. The chemist makes ~500-2000 analogs total. Tools like AlphaFold, structure-based design, and AI guide the optimization.

Step 5: Pre-clinical development (Years 7-9)

Test the lead candidate extensively in animals (rats, dogs, monkeys). Required studies:

  • Pharmacokinetics in animals: confirm the human PK predictions.
  • Toxicology: identify max tolerated doses; identify target organ toxicity.
  • Genotoxicity: ensure no DNA damage.
  • Carcinogenicity (long-term).
  • Reproductive toxicity (especially since thalidomide).
  • Drug-drug interactions: especially CYP3A4.

If all looks good, file an Investigational New Drug (IND) application with the FDA. Approval allows human testing.

Step 6: Clinical trials (Years 9-13)

Phase I (~50 healthy volunteers)

Goal: assess safety and dosing in humans. Find the maximum tolerated dose.

Phase II (~100-300 patients)

Goal: assess efficacy in target disease. Refine dosing.

Phase III (~1000-10000 patients)

Goal: confirm efficacy and safety in larger, more diverse population. Compare to existing treatment.

Each phase typically takes 1-3 years. Successful drugs go from Phase I to approval in 5-7 years (sometimes much longer).

Step 7: FDA approval and post-marketing (Years 13-15+)

NDA (New Drug Application)

If clinical trials succeed, file an NDA with the FDA. Review takes 6-12 months. ~70% of NDAs are approved.

Post-marketing (Phase IV)

After approval, continue to monitor for rare side effects (some only emerge with widespread use). Rare events: hepatotoxicity, cardiovascular events, etc.

Some drugs are withdrawn post-market due to safety issues: - Vioxx (rofecoxib): withdrawn 2004 due to cardiovascular events. - Cerivastatin (Baycol): withdrawn 2001 due to rhabdomyolysis. - Phenformin (a metformin precursor): withdrawn for lactic acidosis.

Failure modes

Of every 10,000 compounds in HTS: - ~100 become hits. - ~10 advance to lead optimization. - ~5 advance to pre-clinical. - ~2-3 enter Phase I. - ~1 reaches market.

Reasons for failure (with rough percentages of those that fail): - Lack of efficacy (~40%): the drug doesn't work in clinical trials. - Safety/toxicity (~30%): side effects are too severe. - Pharmacokinetic problems (~10%): the drug doesn't reach the target at sufficient concentration. - Commercial reasons (~10%): lack of differentiation, market changes. - Strategic reasons (~10%): company priorities shift.

The cost of these failures is borne by the successful drugs — which is why drug prices reflect the high R&D cost of finding the rare success.

Examples of successful drug development

Imatinib (Gleevec, 2001)

  • Target: BCR-ABL kinase in CML.
  • Discovered: 1996 (initial hit).
  • Approved: 2001 (FDA).
  • Impact: transformed CML from fatal to chronic disease.

HIV protease inhibitors (1995-1996)

  • Target: HIV protease.
  • Discovered: structure-based design from HIV protease X-ray.
  • Approved: saquinavir (1995), ritonavir (1996), indinavir (1996).
  • Impact: combined with reverse transcriptase inhibitors → HAART, transforming HIV from death sentence to manageable chronic infection.

Semaglutide (Ozempic / Wegovy, 2017 / 2021)

  • Target: GLP-1 receptor (for type 2 diabetes; later, obesity).
  • Origin: peptide drug, designed from the natural GLP-1 hormone with modifications for stability and potency.
  • Approved: 2017 for diabetes; 2021 for obesity (Wegovy).
  • Impact: transformed obesity treatment; > $20 billion/year drug as of 2024.

Take-home

  • Drug discovery is a 10-15 year, $1-3 billion process integrating chemistry, biology, pharmacology, statistics, and regulatory science.
  • The pipeline: target ID → hit discovery → lead optimization → preclinical → clinical → approval → post-market.
  • 99.99% of candidates fail. Successful drugs require persistence, capital, and chemistry.
  • Modern tools (AI, AlphaFold, automation) are accelerating the process.
  • Examples of recent successes: imatinib, HIV protease inhibitors, semaglutide.
  • Each stage of drug development applies organic chemistry from this textbook (Chapters 24-34) — and increasingly, AI tools that have learned that chemistry from data.
  • The future: AI + automated chemistry → faster, cheaper, more successful drug discovery. The 10-15 year cycle may shrink to 3-5 years in the coming decade.